Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Heart failure (HF) remains a significant global health burden despite therapeutic advancements.
• Understanding HF pathophysiology has driven progress in treatment strategies.

Purpose of the Study:

• To review ongoing clinical trials focused on pharmacotherapy for heart failure.
• To identify key drug classes and novel agents under investigation for HF treatment.

Main Methods:

• Systematic search of clinicaltrials.gov for interventional HF pharmacotherapy trials active as of August 2023.
• Inclusion criteria: trials that were active, recruiting, or not yet recruiting.
• Categorization of interventions by drug class and novelty.

Main Results:

• 119 interventional trials met the inclusion criteria.
• Major intervention categories included novel/repurposed medications (29%), sodium-glucose co-transporter inhibitors (21%), diuretics (14%), angiotensin receptor-neprilysin inhibitors (10%), and mineralocorticoid receptor antagonists (5%).

Conclusions:

• Ongoing research in HF pharmacotherapy is crucial for reducing the impact of the disease.
• The reviewed trials represent the forefront of developing improved HF treatments.